January 17th 2021
By Tony Hagen
The Center for Biosimilars® reports on developments at the International Generic and Biosimilar Medicines Association (IGBA), Celltrion, Innovent Biologics, and Kamada.
January 15th 2021
CMS looks to speed up health information transfer by putting faxes in the past. It also aims to set deadlines for payers to respond to prior authorization requests.
January 11th 2021
Lawrence A. Hill, PharmD, MBA, RPH, BCPS, provided an insider's view of the rapidly changing biologics and biosimilars market and regulatory structure in China.
January 10th 2021
We spoke to Charles Bennett, MD, PhD, a clinical pharmacy specialist, about his recent oncology biosimilars study and how pay-for-delay schemes have somewhat stalled the biosimilar market.
January 9th 2021
Pharmacokinetic (PK) parameters matched up with those of reference trastuzumab in an extended analysis of data from the HERITAGE trial.
January 7th 2021
Authors of a review found that biosimilar uptake and market share are not in themselves sufficient to establish whether these agents will lead to savings.
January 5th 2021
Ivo Abraham, PhD, RN, a professor with the University of Arizona Health Sciences in the Department of Pharmacy Practice and a health care consultant and co-founder of Matrix45, discussed how the pandemic is likely to impact the use of pegfilgrastim biosimilars.
January 4th 2021
Among patients treated for metastatic breast cancer, 40% switched to ABP 980.
January 3rd 2021
An expansion of its Reykjavik, Iceland, headquarters operation will speed the company on its way to launching its first biosimilars, officials said.
January 2nd 2021
By Deana Ferreri, PhD
Providers should feel confident using Mvasi, a bevacizumab biosimilar, for all indications of the reference product (Avastin), reviewers stated.
